Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Research & Development (2018 - 2026)

Immunovant filings provide 8 years of Research & Development readings, the most recent being $98.9 million for Q4 2025.

  • Quarterly Research & Development rose 4.66% to $98.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $408.0 million through Dec 2025, up 22.41% year-over-year, with the annual reading at $360.9 million for FY2025, 69.5% up from the prior year.
  • Research & Development hit $98.9 million in Q4 2025 for Immunovant, down from $114.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $114.2 million in Q3 2025 and bottomed at $18.6 million in Q1 2021.
  • Average Research & Development over 5 years is $58.4 million, with a median of $49.5 million recorded in 2023.
  • The largest annual shift saw Research & Development skyrocketed 102.82% in 2024 before it rose 4.66% in 2025.
  • Immunovant's Research & Development stood at $29.8 million in 2021, then surged by 41.99% to $42.3 million in 2022, then rose by 14.4% to $48.3 million in 2023, then skyrocketed by 95.54% to $94.5 million in 2024, then increased by 4.66% to $98.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Research & Development are $98.9 million (Q4 2025), $114.2 million (Q3 2025), and $101.2 million (Q2 2025).